Home | About | Quick Start | FAQ
Beta Version 0.1
DHARA is an online index of articles on Ayurveda published in research journals worldwide. Users Online: 1984
  Enter Keyword Below :
      
Advanced

Complementary Therapies in Medicine 2022 June ; 66 :102814 [Epub ahead of Print]
AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India

Abstract
Objective: To determine the therapeutic efficacy and safety of AYUSH-64 as an add-on to standard care in mild to moderate COVID-19. Design setting, and interventions: This open-label randomized controlled parallel-group trial was conducted at a designated COVID care centre in India in 80 patients diagnosed with mild to moderate COVID-19 and randomized into two groups. Participants in the AYUSH-64 add-on group (AG) received AYUSH-64 two tablets (500 mg each) three times a day for 30 days along with standard conventional care. The control group (CG) received standard care alone. Main outcome measures: Proportion of participants who attained clinical recovery on day 7, 15, 23 and 30, proportion of participants with negative RT-PCR assay for COVID-19 at each weekly time point, change in pro-inflammatory markers, metabolic functions, HRCT chest (CO-RADS category) and incidence of Adverse Drug Reaction (ADR)/Adverse Event (AE). Results: Out of 80 participants, 74 (37 in each group) contributed to the final analysis. Significant difference was observed in clinical recovery in the AG (p < 0.001 ) compared to CG. Mean duration for clinical recovery in AG (5.8 ± 2.67 days) was significantly less compared to CG (10.0 ± 4.06 days). Significant improvement in HRCT chest was observed in AG (p = 0.031) unlike in CG (p = 0.210). No ADR/SAE was observed or reported in AG. Conclusions: AYUSH-64 as adjunct to standard care is safe and effective in hastening clinical recovery in mild to moderate COVID-19. The efficacy may be further validated by larger multi-center double-blind trials. Keywords: Ayurveda; COVID-19; Integrative medicine; Pandemic; Viral disease.

DHARA ID: D059260 Pubmed ID: 35149205


Link To Full Paper

Replica Louis vuitton Belts Replica Louis vuitton Handbags Replica Louis vuitton Backpack Replica Louis vuitton Capucines Bags Imitazioni Louis vuitton Borse Imitazioni Louis vuitton Cinture Imitazioni Louis vuitton Occhiali Replica Louis vuitton Geldb?rsen Replica Louis vuitton Gürtel Replica Louis vuitton Schmuck Replica Louis vuitton Schal Imitation Louis vuitton Bijoux Imitation Louis vuitton Ceinture Imitation Louis vuitton Chaussures Imitation Louis vuitton Foulard namaak Louis vuitton Gordels namaak Louis vuitton Handtassen namaak Louis vuitton Portemonnees namaak Louis vuitton Schoenen Replica Louis vuitton Bolsos Replica Louis vuitton Billeteras Replica Louis vuitton Cinturones Dior Replica Hermès Replica Yves Saint Laurent Replica Goyard Replica Imitation Louis Vuitton Imitation Hermès Imitation Dior Imitation Yves Saint Laurent Imitazioni Bottega Veneta Borse Imitazioni Delvaux Borse Imitazioni Goyard Borse Replica Taschen Replica Louis Vuitton Replica Hermès Replica Dior Replica Bottega Veneta tassen Replica Chloé tassen Replica Delvaux tassen Replica Goyard tassen imitacion Louis Vuitton imitacion Louis Vuitton imitacion Hermès imitacion Dior Replica Miu Miu Replica Prada Replica Yves Saint Laurent Replica Chanel Replica Gucci Replica Hermès Replica Miu Miu Réplique Chanel Réplique Hermès Réplique Miu Miu Imitazioni Chanel Imitazioni Hermès Imitazioni Miu Miu imitacion Bolso Yves Saint Laurent imitacion Hermes imitacion Chanel imitacion Gucci Gucci Replica Hermes Replica

Copyright | Disclaimer | Feedback | Updates | Contact
Developed and maintained by AVP Research Foundation (Formerly AVT Institute for Advanced Research), 136/137, Trichy Road, Ramanathapuram, Coimbatore - 641045, Tamil Nadu, India
Funded by Central Council for Research in Ayurvedic Sciences, Dept. of AYUSH, Ministry of Health and Family Welfare, Government of India, New Delhi